Cardiac Function as Measured by Non-invasive Electrical Velocimetry Cardiac Monitor in Hospitalized Children
| Status: | Completed |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 1/6/2017 |
| Start Date: | December 2009 |
| End Date: | June 2011 |
A Pilot Study: Cardiac Function as Measured by Non-invasive Electrical Velocimetry Cardiac Monitor in Hospitalized Children From Acute Illness (Disease) to Recovery (Health).
To assess whether a non-invasive cardiac output monitor can follow heart function in
children during treatments in the hospital. To establish a normal reference for children who
are well and awake.
children during treatments in the hospital. To establish a normal reference for children who
are well and awake.
The aim of the study is to evaluate the ability of a new FDA-approved non-invasive
Electrical Velocimetry (EV) cardiac monitor called AESCULON (Cardiotronic Inc, La Jolla CA)
to detect and trend hemodynamic changes in hospitalized ambulatory pediatric patients during
recovery from acute illness. We postulate that if the cardiac monitor can trend hemodynamic
changes in hypertensive patients whose mean arterial pressure (MAP) decreases to normal
levels, or hypotensive patients whose MAP increases to normal levels over several days, it
may improve our understanding of different disease processes and allow us to improve care.
We also seek to establish normative data for different measures provided by the AESCULON
monitor - specifically cardiac output (CO) and systemic vascular resistance (SVR), which are
the prime determinants of MAP.
Electrical Velocimetry (EV) cardiac monitor called AESCULON (Cardiotronic Inc, La Jolla CA)
to detect and trend hemodynamic changes in hospitalized ambulatory pediatric patients during
recovery from acute illness. We postulate that if the cardiac monitor can trend hemodynamic
changes in hypertensive patients whose mean arterial pressure (MAP) decreases to normal
levels, or hypotensive patients whose MAP increases to normal levels over several days, it
may improve our understanding of different disease processes and allow us to improve care.
We also seek to establish normative data for different measures provided by the AESCULON
monitor - specifically cardiac output (CO) and systemic vascular resistance (SVR), which are
the prime determinants of MAP.
Inclusion Criteria:
- Medical patients without complex medical history with expected hospital stay for less
than 10 days
- Uncomplicated Medical Patients as define as (1) Previously healthy children or (2)
Children with diagnosis of a single chronic medical disorder that is not associated
with cardiac dysfunction
Exclusion Criteria:
- Congenital heart disease with and without repair (includes PFO, ASD and PDA, cardiac
valve disease or pulmonary hypertension
- Chronic lung disease (except asthma)
- Abnormal Hemoglobin (SSD)
We found this trial at
1
site
Click here to add this to my saved trials
